Company intelligence / Profile preview
Imaxio
Paris, Île-de-France, Franceimaxio.fr ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Imaxio has developed a marketed vaccine against human leptospirosis in France and leverages its proprietary antigen re-engineering technology to develop new vaccines and companion diagnostics. The company’s R&D led to the creation of Osivax as a spin-off focused on further developing their oligoDOM® antigen engineering technology. The company also applies high-throughput genomics for oncology/immunology diagnostics
- Therapeutic areas
- Infectious Diseases
- Modalities
- Recombinant protein vaccinesAntigen re-engineering platforms
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Not explicitly listed in search results; likely includes collaborations with academic institutions and possibly pharma partners due to diagnostic/vaccine focus.
Beyond the preview
Go deeper on Imaxio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Imaxio.